Maternal blood platelets can provide a reservoir for foetal nucleic acids. We are actively seeking partners for the co-development of platelet-powered prenatal diagnostics.
Prenatal nucleic acid testing has been a fiercely contested market. US prenatal testing was a $1.3 billion market in 2010 of which prenatal diagnostic testing generated the remaining 25%. The clinical utility of microarrays and sequencing in prenatal applications will lay the foundation for tremendous growth in the prenatal diagnostic segment in the years to come.
There are currently only a few major players in the market that mainly focus on detecting trisomies and other aneuploides. Most of these tests are blood-based, but none are based on detection in blood platelets. The market for nucleic acid-based prenatal screening now provides a billion dollar opportunity.